Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
| Market Cap | 141.98M-18.8% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -67.43M+23.2% |
| EPS | -1.17+99.9% |
| Shares Out | 69.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Sep 28, 2017 |
| Volume | 195,348,196.917 |
| Open | 1.99 |
| Previous Close | 0.60 |
| Day's Range | 1.66 - 2.14 |
| 52-Week Range | 0.56 - 2.72 |
| Beta | 1.61 |
| Analysts | Buy |
| Price Target | 4.00(+94.65%) |
| Earnings Date | Nov 10, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Analyst consensus
3 firms rating INO in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 10, 2026Earnings report
Ask Barron about INO
$INO stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in INO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
INO Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Less: | $18.62M | 57.15% |
| Change in fair value of common stock warrant liabilities | $13.87M | 42.56% |
| Net unrealized gain on available-for-sale equity securities | $94.22K | 0.29% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New INO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in INO
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $4.01M |
| VXFVanguard Extended Market ETF | $1.50M |
| IWCiShares Micro-Cap ETF | $153.21K |
| QQQSInvesco NASDAQ Future Gen 200 ETF | $70.18K |
| GERMETFMG Treatments, Testing and Advancements ETF | $48.49K |
| SILXETFMG Prime 2x Daily Junior Silver Miners ETF | $47.24K |
Estimated from each fund’s disclosed top holdings × AUM
INO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from INO’s recent data — informational, not investment advice